1200 cases were newly prescribed by Junshi Biologic for mild to moderate disease

Junshi registered a new phase 3 clinical trial for a COVID-19 drug with ClinicalTrials.gov. A multicenter, double-blind, randomized, placebo-controlled phase III trial was conducted to evaluate the efficacy and safety of JT001 (VV116) in participants with mild-to-moderate COVID-19.

A total of 1200 participants, with a maximum of 1600 participants, were planned to be randomly assigned in a 1:1 ratio to receive JT001 (VV116) or placebo.

The primary end point was the effect of JT001 (VV116) versus placebo on clinical recovery (time range: up to 28 days). Duration of resolution of clinical symptoms.

Secondary end points included the duration of sustained clinical remission, disease progression, viral load, and safety.

Previously, Junshi biological has opened a number of high-risk phase III clinical trials.

Including on May 23, 2022, Junshi Bio and Wangshan Wangshui announced the success of the head-to-head phase 3 clinical trial of VV116 and Huirui P drug. The phase III registration clinical study of VV116 versus PAXLOVID in the early treatment of high-risk patients with mild to moderate COVID-19 met the primary study endpoint.

The phase III clinical trial of Junshi Biological is not necessarily accompanied by high-risk patients of COVID-19, and all of them were high-risk patients before. This time, more people will be eligible and enrolled more rapidly.